Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery

This study is ongoing, but not recruiting participants.

Study NCT00041197 Information provided by National Cancer Institute (NCI)

First Received: July 8, 2002 Last Updated: April 15, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	April 2018 (Final data collection date for primary outcome measure)

Publications:

Sanford M, Scott LJ. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. Drugs. 2010 Oct 22;70(15):1963-72.

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104. Epub 2009 Mar 18.

DeMatteo R, Owzar K, Maki R, et al.: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001. [Abstract] J Clin Oncol 25 (Suppl 18):A-10079, 2007.

ACOSOG Z9001: a phase III randomized double-blind study of adjuvant imatinib mesylate versus placebo in patients following the resection of primary gastrointestinal stromal tumor. Clin Adv Hematol Oncol 2 (5): 310.